Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

NCT02347774 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

641

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD
Chronic Obstructive Pulmonary Disease

Interventions

DRUG: SUN-101 50 mcg BID eFlow (CS) nebulizer
DRUG: SUN-101 25 mcg BID eFlow (CS) nebulizer
DRUG: Placebo eFlow (CS) nebulizer

Sponsor

Sunovion Respiratory Development Inc.